Ares Capital Corporation (ARCC) - Q2 2014 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2014. Ares Capital Corporation is a closed-end, non-diversified management investment company regulated as a Business Development Company (BDC). The Company is externally managed by Ares Capital Management LLC and invests primarily in first lien senior secured loans, second lien senior secured loans, and mezzanine debt, with a lesser focus on equity investments.
Key Financial Metrics
| Metric | Q2 2014 (3 Months) | YTD 2014 (6 Months) | YTD 2013 (6 Months) |
|---|---|---|---|
| Total Investment Income | $224.9 million | $464.6 million | $401.2 million |
| Net Investment Income | $92.0 million | $204.3 million | $192.7 million |
| Net Realized Gains (Losses) | $(48.5) million | $(36.4) million | $20.3 million |
| Net Unrealized Gains | $99.4 million | $92.0 million | $0.8 million |
| Net Increase in Stockholders' Equity | $142.8 million | $259.8 million | $213.8 million |
| Diluted EPS | $0.48 | $0.87 | $0.83 |
| Total Assets | $8.56 billion | As of June 30, 2014 | |
| Total Debt (Carrying Value) | $3.36 billion | ||
| Cash and Cash Equivalents | $223.2 million | As of June 30, 2014 | |
| Net Assets Per Share | $16.52 |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased 9.1% year-over-year for the six months ended June 30, 2014, driven primarily by an increase in the average portfolio size (from $6.1 billion to $7.7 billion at amortized cost) and higher capital structuring fees.
- Realized Losses: The Company reported net realized losses of $36.4 million for the six months ended June 30, 2014, compared to net realized gains of $20.3 million in the prior year period. Significant losses were attributed to sales/repayments of investments in CitiPostal Inc. ($20.2 million loss) and MVL Group, Inc. ($27.7 million loss).
- Unrealized Gains: Net unrealized gains were $92.0 million for the six months ended June 30, 2014, a significant increase from $0.8 million in the prior year period. Key contributors to appreciation included Insight Pharmaceuticals Corporation ($24.0 million) and The Dwyer Group ($10.1 million).
- Expense Increases: Total expenses rose to $252.0 million (YTD 2014) from $200.8 million (YTD 2013). This increase was driven by higher interest and credit facility fees ($105.6 million vs. $79.6 million) due to increased debt levels, and higher management fees due to the larger asset base.
Guidance, Outlook, and Risks
- Portfolio Composition: As of June 30, 2014, the portfolio consisted of 85.1% Grade 3 investments and 11.2% Grade 4 investments. Only 0.6% of the portfolio was Grade 1 (highest risk). Loans on non-accrual status represented 1.9% of total investments at amortized cost, down from 3.1% at year-end 2013.
- Senior Secured Loan Program (SSLP): The Company continues to co-invest with GE in the SSLP. The Company's yield on its SSLP investment was 13.9% at fair value as of June 30, 2014. The SSLP portfolio had one loan on non-accrual status (0.9% of total loans).
- Liquidity and Capital: The Company had $223.2 million in cash and approximately $1.8 billion available for additional borrowings under its credit facilities. Asset coverage was 247%, well above the 200% regulatory minimum.
- Subsequent Event: In July 2014, the Company completed a public equity offering of 15.5 million shares at $16.63 per share, raising approximately $257.7 million in net proceeds to repay debt and fund new investments.
- Risks: The filing highlights standard BDC risks including credit risk, interest rate risk, and liquidity risk. A specific litigation risk involves a lawsuit filed by the bankruptcy trustee of DSI Renal Holdings LLC, seeking damages of approximately $117 million from the Company; management believes the claims are without merit.
Key Facts for Investor Verification
- Realized Loss Drivers: Verify the specific circumstances surrounding the $20.2 million realized loss on CitiPostal Inc. and the $27.7 million loss on MVL Group, Inc., as these significantly impacted YTD earnings.
- Unrealized Gain Sustainability: Assess the valuation methodology for the $92.0 million in unrealized gains, particularly the $24.0 million appreciation in Insight Pharmaceuticals Corporation, to ensure they are not overly reliant on optimistic market assumptions.
- Debt Maturity Profile: Review the weighted average maturity of 7.2 years and the specific terms of the Convertible Unsecured Notes (maturing 2016-2019) to understand refinancing risks.
- Non-Accrual Trends: Monitor the reduction in non-accrual loans from 3.1% to 1.9% to confirm the improvement in credit quality is sustainable.
- July 2014 Equity Offering: Confirm the deployment of the $257.7 million raised in July 2014 and its impact on the leverage ratio and asset coverage in the subsequent quarter.